# Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

> **NCT07215637** · PHASE1 · RECRUITING · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** CKD-512
- **COMBINATION_PRODUCT:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07215637
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2027-03
- **Final completion:** 2027-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07215637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07215637, "Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07215637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*